136 related articles for article (PubMed ID: 34545366)
1. Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates.
Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
bioRxiv; 2021 Sep; ():. PubMed ID: 34545366
[TBL] [Abstract][Full Text] [Related]
2. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.
Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
NPJ Vaccines; 2022 Jan; 7(1):7. PubMed ID: 35064109
[TBL] [Abstract][Full Text] [Related]
3. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants.
Wussow F; Kha M; Kim T; Ly M; Yll-Pico M; Kar S; Lewis MG; Chiuppesi F; Diamond DJ
NPJ Vaccines; 2023 Mar; 8(1):41. PubMed ID: 36928589
[TBL] [Abstract][Full Text] [Related]
4. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants.
Wussow F; Kha M; Faircloth K; Nguyen VH; Iniguez A; Martinez J; Park Y; Nguyen J; Kar S; Andersen H; Lewis MG; Chiuppesi F; Diamond DJ
iScience; 2022 Jun; 25(6):104457. PubMed ID: 35634578
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Chiuppesi F; Ortega-Francisco S; Gutierrez MA; Li J; Ly M; Faircloth K; Mack-Onyeike J; La Rosa C; Thomas S; Zhou Q; Drake J; Slape C; Fernando P; Rida W; Kaltcheva T; Grifoni A; Sette A; Patterson A; Dempsey S; Ball B; Ali H; Salhotra A; Stein A; Nathwani N; Rosenzweig M; Nikolaenko L; Al Malki MM; Dickter J; Nanayakkara DD; Puing A; Forman SJ; Taplitz RA; Zaia JA; Nakamura R; Wussow F; Diamond DJ; Dadwal SS
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766168
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants.
Chiuppesi F; Zaia JA; Faircloth K; Johnson D; Ly M; Karpinski V; La Rosa C; Drake J; Marcia J; Acosta AM; Dempsey S; Taplitz RA; Zhou Q; Park Y; Ortega Francisco S; Kaltcheva T; Frankel PH; Rosen S; Wussow F; Dadwal S; Diamond DJ
iScience; 2022 Aug; 25(8):104745. PubMed ID: 35846380
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.
Chiuppesi F; Zaia JA; Frankel PH; Stan R; Drake J; Williams B; Acosta AM; Francis K; Taplitz RA; Dickter JK; Dadwal S; Puing AG; Nanayakkara DD; Ash P; Cui Y; Contreras H; La Rosa C; Tiemann K; Park Y; Medina J; Iniguez A; Zhou Q; Karpinski V; Johnson D; Faircloth K; Kaltcheva T; Nguyen J; Kha M; Nguyen VH; Francisco SO; Grifoni A; Wong A; Sette A; Wussow F; Diamond DJ
Lancet Microbe; 2022 Apr; 3(4):e252-e264. PubMed ID: 35287430
[TBL] [Abstract][Full Text] [Related]
8. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
Chiuppesi F; Zaia JA; Gutierrez-Franco MA; Ortega-Francisco S; Ly M; Kha M; Kim T; Dempsey S; Kar S; Grifoni A; Sette A; Wussow F; Diamond DJ
Commun Med (Lond); 2024 Feb; 4(1):19. PubMed ID: 38366141
[TBL] [Abstract][Full Text] [Related]
9. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
[TBL] [Abstract][Full Text] [Related]
10. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
van der Lubbe JEM; Rosendahl Huber SK; Vijayan A; Dekking L; van Huizen E; Vreugdenhil J; Choi Y; Baert MRM; Feddes-de Boer K; Izquierdo Gil A; van Heerden M; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; de Waal L; Stittelaar KJ; Tolboom JTBM; Serroyen J; Muchene L; van der Fits L; Rutten L; Langedijk JPM; Barouch DH; Schuitemaker H; Zahn RC; Wegmann F
NPJ Vaccines; 2021 Mar; 6(1):39. PubMed ID: 33741993
[TBL] [Abstract][Full Text] [Related]
11. Oral Administration of Universal Bacterium-Vectored Nucleocapsid-Expressing COVID-19 Vaccine is Efficacious in Hamsters.
Jia Q; Bielefeldt-Ohmann H; Maison RM; Hartwig A; Masleša-Galić S; Bowen RA; Horwitz MA
Microbiol Spectr; 2023 Mar; 11(2):e0503522. PubMed ID: 36916971
[TBL] [Abstract][Full Text] [Related]
12. A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
Bricker TL; Darling TL; Hassan AO; Harastani HH; Soung A; Jiang X; Dai YN; Zhao H; Adams LJ; Holtzman MJ; Bailey AL; Case JB; Fremont DH; Klein R; Diamond MS; Boon ACM
bioRxiv; 2020 Dec; ():. PubMed ID: 33299991
[TBL] [Abstract][Full Text] [Related]
13. MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge.
Meseda CA; Stauft CB; Selvaraj P; Lien CZ; Pedro C; Nuñez IA; Woerner AM; Wang TT; Weir JP
NPJ Vaccines; 2021 Dec; 6(1):145. PubMed ID: 34862398
[TBL] [Abstract][Full Text] [Related]
14. A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
Bricker TL; Darling TL; Hassan AO; Harastani HH; Soung A; Jiang X; Dai YN; Zhao H; Adams LJ; Holtzman MJ; Bailey AL; Case JB; Fremont DH; Klein R; Diamond MS; Boon ACM
Cell Rep; 2021 Jul; 36(3):109400. PubMed ID: 34245672
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
16. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
Hassan AO; Feldmann F; Zhao H; Curiel DT; Okumura A; Tang-Huau TL; Case JB; Meade-White K; Callison J; Lovaglio J; Hanley PW; Scott DP; Fremont DH; Feldmann H; Diamond MS
bioRxiv; 2021 Jan; ():. PubMed ID: 33532770
[TBL] [Abstract][Full Text] [Related]
17. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
18. Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.
Li C; Chen YX; Liu FF; Lee AC; Zhao Y; Ye ZH; Cai JP; Chu H; Zhang RQ; Chan KH; Chiu KH; Lung DC; Sridhar S; Hung IF; To KK; Zhang AJ; Chan JF; Yuen KY
Clin Infect Dis; 2021 Aug; 73(3):e719-e734. PubMed ID: 33515458
[TBL] [Abstract][Full Text] [Related]
19. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
Chiuppesi F; Salazar MD; Contreras H; Nguyen V; Martinez J; Park S; Nguyen J; Kha M; Iniguez A; Zhou Q; Kaltcheva T; Levytskyy R; Ebelt N; Kang T; Wu X; Rogers T; Manuel E; Shostak Y; Diamond D; Wussow F
Res Sq; 2020 Jul; ():. PubMed ID: 32702732
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.
Joyce MG; King HAD; Naouar IE; Ahmed A; Peachman KK; Cincotta CM; Subra C; Chen RE; Thomas PV; Chen WH; Sankhala RS; Hajduczki A; Martinez EJ; Peterson CE; Chang WC; Choe M; Smith C; Lee PJ; Headley JA; Taddese MG; Elyard HA; Cook A; Anderson A; McGuckin-Wuertz K; Dong M; Swafford I; Case JB; Currier JR; Lal KG; O'Connell RJ; Molnar S; Nair MS; Dussupt V; Daye SP; Zeng X; Barkei EK; Staples HM; Alfson K; Carrion R; Krebs SJ; Paquin-Proulx D; Karasavva N; Polonis VR; Jagodzinski LL; Amare MF; Vasan S; Scott PT; Huang Y; Ho DD; de Val N; Diamond MS; Lewis MG; Rao M; Matyas GR; Gromowski GD; Peel SA; Michael NL; Bolton DL; Modjarrad K
bioRxiv; 2021 Mar; ():. PubMed ID: 33791694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
